 From July 2016 it became a “managed access” fund, paying for new drugs for a set period before they are definitively approved or rejected by the National Institute for Health and Care Excellence.It did not accept any new drugs between April and July 2016.From 2016 each drug has evaluation criteria and a timescale for effectiveness to be assessed.